ethyl 4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: ethyl 4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
• 英文别名: ethyl 4-cyclohexylamino-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate；ethyl 4-(cyclohexylamino)-1-ethylpyrazolo[3,4-b]pyridine-5-carboxylate
• 化学式: C₁₇H₂₄N₄O₂
• 分子量: 316.403
• InChiKey: DDAUUBIDZKMIDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  69
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 在 乙醇 、 sodium hydroxide 作用下， 反应 10.0h， 生成 4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
  参考文献：
  名称：

  Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer’s disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids

  摘要：

  A series of tacrine-pyrazolo [3,4-b]pyridine hybrids were synthesised and evaluated as dual cholinesterase (ChE) and phosphodiesterase 4D (PDE4D) inhibitors for the treatment of Alzheimer's disease (AD). Compound 10j, which is tacrine linked with pyrazolo[3,4-b]pyridine moiety by a six-carbon spacer, was the most potent acetylcholinesterase (AChE) with IC50 value of 0.125 mu M. Moreover, compound 10j provided a desired balance of AChE and butylcholinesterase (BuChE) and PDE4D inhibition activities, with IC50, value of 0.449 and 0.271 mu M, respectively. The above results indicated that this hybrid was a promising dual functional agent for the treatment of AD.

  DOI：

  10.1016/j.bmcl.2019.06.056
• 作为产物：
  描述：

  5-氨基-1-乙基吡唑 在 三乙胺 、 三氯氧磷 作用下， 反应 34.0h， 生成 ethyl 4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
  参考文献：
  名称：

  Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer’s disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids

  摘要：

  A series of tacrine-pyrazolo [3,4-b]pyridine hybrids were synthesised and evaluated as dual cholinesterase (ChE) and phosphodiesterase 4D (PDE4D) inhibitors for the treatment of Alzheimer's disease (AD). Compound 10j, which is tacrine linked with pyrazolo[3,4-b]pyridine moiety by a six-carbon spacer, was the most potent acetylcholinesterase (AChE) with IC50 value of 0.125 mu M. Moreover, compound 10j provided a desired balance of AChE and butylcholinesterase (BuChE) and PDE4D inhibition activities, with IC50, value of 0.449 and 0.271 mu M, respectively. The above results indicated that this hybrid was a promising dual functional agent for the treatment of AD.

  DOI：

  10.1016/j.bmcl.2019.06.056

文献信息

• Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
  申请人：Edlin Christopher David

  公开号：US20090131431A1

  公开（公告）日：2009-05-21

  The invention provides a compound of formula (I) or a salt thereof: wherein R 2 is H, C 1-3 alkyl, n-butyl, C 1-2 fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl-, —CN, or —CH 2 OH; R 3 is inter alia optionally substituted C 4-7 cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); R a is H, methyl or ethyl; R b is H or methyl; R 4 is H, methyl, ethyl, n-propyl, —C(O)-Me, or —C(O)—C 1 fluoroalkyl; and R 5 is: —C(O)—(CH 2 ) n —Ar, —C(O)-Het, —C(O)—C 1-6 alkyl, —C(O)—C 1 fluoroalkyl, —C(O)—(CH 2 ) 2 —C(O)—NR 15b NR 15b , —C(O)—CH 2 —C(O)—NR 15b NR 15b , —C(O)—NR 15b —(CH 2 )m 1 —Ar, —C(O)—NR 15b —Het, —C(O)—NR 15b —C 1-6 alkyl, —C(O)—NR 5a R 5b , —S(O) 2 —(CH 2 ) m 2 —Ar, —S(O) 2 -Het, —S(O) 2 —C 1-6 alkyl, or —CH 2 —Ar; or R 4 and R 5 taken together are —(CH 2 ) p 1 —, —(CH 2 ) 2 —X 5 —(CH 2 ) 2 —, —C(O)—(CH 2 ) p 2 —, —C(O)—N(R 15 )—(CH 2 ) p 3 —; or NR 4 R 5 is of sub-formula (y), (y1), (y2) or (y3). The invention provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as COPD and the like.

  该发明提供了化合物的结构式(I)或其盐：其中R2为H、C1-3烷基、正丁基、C1-2氟烷基、环丙基、环丁基、(环丙基)甲基、—CN或—CH2OH；R3为可选择地取代的C4-7环烷基或可选择地取代的杂环基(aa)、(bb)或(cc)；R为H、甲基或乙基；R为H或甲基；R为H、甲基、乙基、正丙基、—C(O)-甲基或—C(O)—C1氟烷基；以及R为：—C(O)—(CH2)n—Ar、—C(O)-Het、—C(O)—C1-6烷基、—C(O)—C1氟烷基、—C(O)—(CH2)2—C(O)—NR15bNR15b、—C(O)—CH2—C(O)—NR15bNR15b、—C(O)—NR15b—(CH2)m1—Ar、—C(O)—NR15b—Het、—C(O)—NR15b—C1-6烷基、—C(O)—NR5aR5b、—S(O)2—(CH2)m2—Ar、—S(O)2-Het、—S(O)2—C1-6烷基或—CH2—Ar；或R和R5一起为—(CH2)p1—、—(CH2)2—X5—(CH2)2—、—C(O)—(CH2)p2—、—C(O)—N(R15)—(CH2)p3—；或NR4R5为子式(y)、(y1)、(y2)或(y3)。该发明提供了这些化合物作为磷酸二酯酶IV型(PDE4)的抑制剂以及用于治疗和/或预防炎症和/或过敏性疾病，如慢性阻塞性肺病(COPD)等的用途。
• Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
  申请人：Allen George David

  公开号：US20060089375A1

  公开（公告）日：2006-04-27

  The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl, —CH 2 CH 2 OH or —CH 2 CH 2 CO 2 C 1-2 alkyl; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3 is optionally substituted C 3-8 cycloalkyl or optionally substituted mono-unsaturated-C 5-7 cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n 1 and n 2 independently are 1 or 2; and in which Y is O, S, SO 2 , or NR 10 ; or R 3 is a bicyclic group (dd) or (ee): and wherein X is NR 4 R 5 or OR 5a . The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

  本发明涉及一种化合物或其盐，其化学式为（I）：其中：R1为C1-4烷基，C1-3氟烷基，-CH2CH2OH或-CH2CH2CO2C1-2烷基；R2为氢原子（H），甲基或C1氟烷基；R3为可选取代的C3-8环烷基或可选取代的单不饱和C5-7环烯基或亚式（aa），（bb）或（cc）的可选取代的杂环基；其中n1和n2独立地为1或2；且其中Y为O，S，SO2或NR10；或者R3为双环基（dd）或（ee）：其中X为NR4R5或OR5a。该化合物为磷酸二酯酶（PDE）抑制剂，特别是PDE4抑制剂。本发明还提供了使用化合物（I）或其药学上可接受的盐制造药物，用于治疗和/或预防哺乳动物（例如人类）的炎症和/或过敏性疾病，例如慢性阻塞性肺疾病（COPD），哮喘或过敏性鼻炎。
• Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
  申请人：Allen George David

  公开号：US20080058369A1

  公开（公告）日：2008-03-06

  The invention provides N-[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-(8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide, whose formula is , or a salt thereof, such as the monohydrochloride salt thereof. The invention also provides the use of the compound or salt as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, or rhinitis (e.g. allergic and/or non-allergic rhinitis).

  本发明提供一种N-[1,6-二乙基-4-(四氢-2H-吡喃-4-基氨基)-1H-吡唑并[3,4-b]吡啶-5-基]甲基}-4-(8-[(2-羟乙基)(甲基)氨基]辛酰}氨基)苯甲酰胺，其化学式为，或其盐，例如单盐酸盐。本发明还提供该化合物或盐作为磷酸二酯酶IV (PDE4) 的抑制剂以及/或用于治疗和/或预防炎症和/或过敏性疾病，如慢性阻塞性肺疾病 (COPD)，哮喘或鼻炎 (如过敏性和/或非过敏性鼻炎)。
• PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
  申请人：Allen David George

  公开号：US20090318494A1

  公开（公告）日：2009-12-24

  The invention provides a compound of formula (I) or a salt thereof: wherein Ar has the sub-formula (w), (y), (z1) or (z2): wherein the several groups are defined herein below, and the use of these compounds as inhibitors of phosphodiesterase type IV (PDE4).

  本发明提供了式(I)的化合物或其盐：其中Ar具有子式(w)，(y)，(z1)或(z2)：其中各个基团在下文中定义，并使用这些化合物作为磷酸二酯酶IV型（PDE4）的抑制剂。
• PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS
  申请人：Allen David George

  公开号：US20090326003A1

  公开（公告）日：2009-12-31

  The present invention provides a compound of formula (I) or a salt thereof (in particular, a pharmaceutically acceptable salt thereof): The invention also provides the use of the compounds or salts as inhibitors of phosphodiesterase type IV (PDE4) for the treatment or prophylaxis of inflammatory or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis, atopic dermatitis or psoriasis, e.g. in a mammal such as a human.

  本发明提供了式（I）的化合物或其盐（特别是其药学上可接受的盐）：本发明还提供了将该化合物或盐用作磷酸二酯酶IV（PDE4）的抑制剂，用于治疗或预防炎症或过敏性疾病，如慢性阻塞性肺疾病（COPD），哮喘，鼻炎，特应性皮炎或银屑病，例如在哺乳动物，如人类中。